Physostigmine

A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.

Also Known As:

Networked: 939 relevant articles (67 outcomes, 93 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Weigand, Markus A: 8 articles (10/2019 - 04/2010)
2.	Hofer, Stefan: 6 articles (01/2019 - 04/2010)
3.	Hoppe-Tichy, Torsten: 4 articles (10/2019 - 07/2015)
4.	Pinder, Nadine: 4 articles (10/2019 - 07/2015)
5.	Swoboda, Stefanie: 4 articles (10/2019 - 07/2015)
6.	Zimmermann, Johannes B: 4 articles (10/2019 - 07/2015)
7.	Brenner, Thorsten: 4 articles (01/2019 - 07/2015)
8.	Kopitz, Jürgen: 4 articles (10/2018 - 09/2010)
9.	Plaschke, Konstanze: 4 articles (10/2018 - 09/2010)
10.	Aas, Pål: 4 articles (01/2014 - 05/2004)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/01/1994 - "Physostigmine has been reported to improve the memory function of some patients with Alzheimer's Disease (AD). " 04/01/1993 - "Physostigmine ameliorates the delusions of Alzheimer's disease." 02/01/1993 - "Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease." 02/01/1990 - "To assess the efficacy of oral physostigmine for the treatment of Alzheimer's disease, 20 patients were entered into a clinical trial. " 12/01/2009 - "This study will facilitate the rational design of more potent Physostigmine compounds which might have better activity and reduce toxicity for the treatment of Alzheimer disease."
2.	Poisoning 01/01/2019 - "Logistic regression analysis was used to identify potential predictors of the severity of poisoning; bivariate analysis was employed to assess the effectiveness of physostigmine in the treatment of Datura/Brugmansia poisoning. " 03/01/2011 - "Physostigmine (0.8 mg/kg im) at 1 min after poisoning increased mortality. " 12/01/1994 - "Reversal of tall larkspur (Delphinium barbeyi) poisoning in cattle with physostigmine." 01/01/1991 - "As for the diaphragm, AChE activity in THA-pretreated animals was 29% of controls 10 min after poisoning versus 8 and 23% in unprotected and physostigmine-pretreated animals, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)" 01/01/1991 - "At 24 h after poisoning, brain AChE activity averaged 34 and 47% of that in controls in the mice protected by THA and physostigmine, respectively. "
3.	Delirium 01/01/2019 - "We observed delirium control in 79% of patients who received physostigmine versus 36% of those who did not. " 01/01/2018 - "This case also highlights the need for observation after resolution of delirium treated with physostigmine." 08/01/2002 - "The patient presented with acute delirium and was successfully treated with physostigmine." 01/01/2000 - "Physostigmine controlled agitation and reversed delirium in 96% and 87% of patients, respectively. " 08/01/1987 - "Physostigmine reversed the delirium in one patient. "
4.	Dementia (Dementias) 01/01/1985 - "Efficacy of oral physostigmine in primary degenerative dementia. " 01/01/2001 - "All relevant unconfounded, double-blind, randomized, placebo-controlled trials in which physostigmine was administered for more than one day to patients with dementia of Alzheimer type. " 01/01/2001 - "Studies conducted more than 20 years ago suggested that physostigmine could improve memory in people with or without dementia. " 01/01/1993 - "Nine patients with primary degenerative dementia (PDD) participated in an open trial of transdermal physostigmine (TPh). " 01/01/1990 - "Oral physostigmine as treatment for dementia of the Alzheimer type: a long-term outpatient trial."
5.	Memory Disorders (Memory Loss) 02/01/2008 - "Physostigmine (50 microg/kg) fully reversed memory deficits in the Ts65Dn mice in the 4-month-old group but not in older mice. " 04/01/1985 - "Learning and memory deficits after lesions of the nucleus basalis magnocellularis: reversal by physostigmine." 04/01/1985 - "Physostigmine reverses memory deficits produced by pretraining electrical stimulation of the dorsal hippocampus in mice." 03/01/1982 - "Physostigmine in the treatment of memory disorders: a case report." 06/01/2019 - "Oxotremorine and physostigmine significantly improved the learning and memory deficits as well as the suppression of LTP in PBOCCA rats. "

Related Drugs and Biologics

1.	Soman
2.	Cholinesterase Inhibitors (Anticholinesterases)
3.	Scopolamine (Hyoscine)
4.	Atropine
5.	Donepezil (Aricept)
6.	Tacrine (Cognex)
7.	Cholinergic Agents (Cholinergics)
8.	Cholinergic Antagonists (Anticholinergics)
9.	Cholinesterases (Cholinesterase)
10.	Antipsychotic Agents (Antipsychotics)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Infusions
3.	Intravenous Injections
4.	Intravenous Administration
5.	Oral Administration